LONA — LeonaBio, Inc.

Summary of Athira Pharma Q4 2021 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $54.9 million, or $1.49 per share, for the year ended December 31, 2021, compared to a net loss of $19.9 million, or $1.67 per share, in 2020.
• Research and Development Expenses: Increased to $42.8 million from $13.3 million, driven by heightened clinical trial activities and expanded personnel.
• General and Administrative Expenses: Rose to $21.2 million from $6.7 million, attributed to increased headcount and infrastructure costs.
• Cash Position: Ended 2021 with $319.7 million in cash and investments, up from $268.2 million in 2020, providing a solid foundation for ongoing clinical programs.

2. Strategic Updates and Business Highlights

• Clinical Progress: Dosing of the first patient in the Phase 2 study of fosgonimeton (fosgo) for Parkinson's disease dementia and dementia with Lewy bodies has commenced.
• ACT-AD and LIFT-AD Studies: Enrollment for the Phase 2 ACT-AD study was completed, with top-line data expected in Q2 2022. The Phase 3 LIFT-AD study is on track to complete enrollment by Q3 2022.
• Board Expansion: Two new members with extensive industry experience were added to the Board of Directors, enhancing leadership capabilities.
• Focus on HGF/MET System: Athira is advancing its unique approach to treating neurodegenerative diseases by targeting the HGF/MET neurotrophic system.

3. Forward Guidance and Outlook

• Data Expectations: Anticipates reporting top-line data from the ACT-AD study in Q2 2022, with potential insights to optimize the LIFT-AD study.
• Enrollment Goals: Aiming to complete enrollment for the LIFT-AD study by the end of Q3 2022, with data readouts expected in the first half of 2023.
• Market Opportunity: The company highlighted a significant unmet need in Alzheimer's treatment, with a growing patient population and limited existing therapies.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The substantial increase in net loss year-over-year raises concerns about the sustainability of current spending levels without immediate revenue generation.
• Dependence on Clinical Trial Outcomes: Success hinges on the outcomes of ongoing clinical trials, particularly the ACT-AD and LIFT-AD studies, which carry inherent risks and uncertainties.
• Market Competition: The Alzheimer’s treatment market is undersupplied, but the presence of other players could intensify competition as new therapies emerge.

5. Notable Q&A Insights

• ACT-AD Data Sharing: Management indicated that while they will report primary endpoint results, detailed efficacy curves for secondary endpoints may not be shared immediately.
• Cognitive and Functional Endpoints: There is an expectation that both cognitive and functional endpoints will be necessary for regulatory approval in the LIFT-AD study, with flexibility in selecting which functional scales to use.
• Enrollment Dynamics: The company remains optimistic about enrollment rates despite potential challenges posed by external factors like the COVID-19 pandemic.

Overall, Athira Pharma is positioned for a pivotal year with significant clinical milestones ahead, although it faces challenges related to financial sustainability and trial outcomes.